<think>
Okay, let's try to figure out this question. So, the patient is an 82-year-old woman with a 45 pack-year smoking history, quit 15 years ago. She has a 1-year history of worsening cough and shortness of breath. Her vital signs include a temperature of 36.8°C (98.2°F), blood pressure 140/90 mmHg, heart rate 105/min, oxygen saturation at rest 92% on room air, and 84% when walking. ECG is normal, and FEV1/FVC ratio is 65% of predicted. The question is about the most appropriate inhaled medication for her, and which receptor it blocks. The options are beta1-adrenergic, glucocorticoid, histamine H1, leukotriene, or muscarinic receptors.

First, let's think about the symptoms. She's 82, smoker, FEV1/FVC 65% of predicted. FEV1/FVC ratio is a measure of airflow obstruction, which is a key indicator of chronic obstructive pulmonary disease (COPD). So, she's likely a COPD patient. The symptoms of COPD include chronic cough, sputum production, and shortness of breath, which align with her history of worsening cough and shortness of breath over a year.

Now, the question is about the most appropriate inhaled medication. Inhaled medications for COPD are typically bronchodilators or corticosteroids. Let's go through the options.

Option A: Beta1-adrenergic receptors. Beta1 receptors are mainly in the heart, so beta2 agonists like albuterol work on beta2 receptors in the lungs to relax smooth muscles. But beta1 is less relevant here. So probably not A.

Option B: Glucocorticoid receptors. Inhaled corticosteroids like fluticasone or budesonide block glucocorticoid receptors. They reduce inflammation and mucus production. But the question is about the most appropriate inhaled medication. For COPD, the mainstay is long-acting bronchodilators. Glucocorticoids are adjunctive, maybe in severe cases, but not the primary choice. So maybe B is a possibility, but not the most appropriate.

Option C: Histamine H1 receptors. Antihistamines like diphenhydramine block H1 receptors, but that's for allergies, not COPD. COPD is not primarily an allergic condition. So C is unlikely.

Option D: Leukotriene receptors. Leukotriene modifiers like montelukast block leukotriene receptors, reducing inflammation. But again, COPD is more about bronchodilation. Leukotriene inhibitors are used in asthma, but maybe in COPD as well. However, the most common inhaled medications are bronchodilators. So D is possible but maybe not the first choice.

Option E: Muscarinic receptors. Inhaled anticholinergics like ipratropium block muscarinic receptors (M3 subtype), which are involved in bronchoconstriction. They relax smooth muscles in the airways. So this is a bronchodilator. Since the patient has airflow obstruction, a bronchodilator would be appropriate. The question is which receptor it blocks. So E is the answer.

Wait, but let me confirm. The options are asking which receptor the medication blocks. So if the medication is a bronchodilator, it would block muscarinic receptors. So E is correct. The other options are either not used in COPD (A, C, D) or not the primary choice (B). So yes, E is the most appropriate.
</think>

The patient's history of COPD (FEV1/FVC 65% of predicted) and symptoms of airflow obstruction align with chronic bronchitis or emphysema. The most appropriate inhaled medication for COPD is a bronchodilator. Among the options, **E. muscarinic receptors** are blocked by anticholinergics like ipratropium, which relax smooth muscles in the airways. Other options (A, C, D) are less relevant for COPD, and B (glucocorticoids) is adjunctive rather than primary. 

**Answer:** E. muscarinic receptors